^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH1 mutation + MGMT promoter methylation

    i
    Other names: MGMT, Methylated-DNA--protein-cysteine methyltransferase, 6-O-methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase, HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
    Entrez ID:
    3417; 4255
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Daniela A. Bota | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Sep 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
    |
    Avastin (bevacizumab)
    over1year
    Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis. (PubMed, J Neuropathol Exp Neurol)
    In conclusion, H3K36me2 may be considered as a potential biomarker for glioma diagnosis, grading, and prognosis, but the overall clinical value of H3K36me2 determination deserves further investigation. These results may have important implications for accurate diagnosis and future precision treatment of gliomas.
    Journal
    |
    TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    TP53 mutation • IDH1 mutation • MGMT promoter methylation • TP53 expression • IDH1 mutation + MGMT promoter methylation
    3years
    Role of Radiotherapy in Management of Primary Spinal High Grade Glioma: A single institution retrospective analysis (SNO 2021)
    65% patients received concurrent chemotherapy, most commonly temozolomide...CONCLUSIONS Although 86% of patients had gross disease at RT and received a lower median RT dose than typically used in cerebral high-grade gliomas, only 55% of patients failed locally. H3K27M mutation may portend worse survival; future studies to improve the therapeutic approach in these patients are warranted.
    Retrospective data
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
    |
    temozolomide
    over3years
    The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents. (PubMed, Pathol Oncol Res)
    Although IDH1-mutant glioblastomas showed late tumor recurrence in patients less than 50 years old, the type of treatment modalities may not show additional beneficial outcome. Patients with unmethylated MGMT and IDH1 mutation, treated with different chemoradiotherapies, showed a late tumor recurrence.
    Clinical • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
    over3years
    Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma (clinicaltrials.gov)
    P2, N=34, Recruiting, Daniela A. Bota | N=26 --> 34
    Clinical • Enrollment change
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
    |
    Avastin (bevacizumab)
    over4years
    Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Daniela A. Bota | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH1 mutation • MGMT promoter methylation • IDH1 mutation + MGMT promoter methylation
    |
    Avastin (bevacizumab)